Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Hep C Nucleoside Scare: FDA Wants Idenix’s CV Safety Data After BMS Event

This article was originally published in The Pink Sheet Daily

Executive Summary

Idenix announced FDA has placed a partial clinical hold on its hepatitis C candidate IDX184 after Bristol-Myers Squibb was forced to halt a study of its similar drug following a serious cardiovascular event. The news sparked new worries concerning a class effect for nucleoside polymerase inhibitors, though Gilead stood by its candidate GS7977’s clean CV profile and Idenix said no CV toxicities have been associated with ‘184.

You may also be interested in...

Decompensated Cirrhosis May Be Another HCV Edge For Gilead; Bristol, J&J Still In Contention

Bristol and Johnson & Johnson have not abandoned their efforts to take a relevant place in the HCV market, although J&J isn't expected to produce triple combination data until next year.

Sovaldi, Harvoni Face First Safety Issue With Post-Marketing Cardiac Events

Gilead issues “Dear Healthcare Provider” letter outlining nine cases of bradycardia in patients who received amiodarone in combination with one of its HCV polymerase inhibitors; FDA has updated labeling for both drugs.

Achillion Readies A Nuc Combo As Acquisition Speculation Swirls

The biotech can move forward with an HCV combo that includes its Phase I nuc and its protease inhibitor now that FDA has partially lifted the hold on the drug.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts